Joseph Stringer
Stock Analyst at Needham
(4.40)
# 362
Out of 5,113 analysts
311
Total ratings
48%
Success rate
21.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Buy | $29 → $28 | $23.07 | +21.37% | 21 | Jan 13, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $520 → $529 | $349.58 | +51.32% | 24 | Jan 12, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $145 → $148 | $102.67 | +44.15% | 29 | Jan 9, 2026 | |
| PCVX Vaxcyte | Maintains: Buy | $90 → $110 | $51.37 | +114.13% | 18 | Jan 7, 2026 | |
| GILD Gilead Sciences | Maintains: Buy | $133 → $140 | $139.72 | +0.20% | 9 | Nov 13, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $78 → $90 | $81.92 | +9.86% | 25 | Oct 30, 2025 | |
| RNA Avidity Biosciences | Downgrades: Hold | $65 | $72.46 | -10.30% | 19 | Oct 27, 2025 | |
| MRNA Moderna | Reiterates: Hold | n/a | $45.30 | - | 9 | Oct 20, 2025 | |
| STOK Stoke Therapeutics | Maintains: Buy | $22 → $35 | $29.40 | +19.05% | 24 | Oct 10, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $28 | $13.84 | +102.31% | 52 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $7.57 | +84.94% | 18 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $11 | $6.29 | +74.88% | 19 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $477.91 | - | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.50 | - | 13 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 | $1.25 | +700.00% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $37 | $25.62 | +44.42% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $19.03 | -5.41% | 2 | Aug 24, 2021 |
Apellis Pharmaceuticals
Jan 13, 2026
Maintains: Buy
Price Target: $29 → $28
Current: $23.07
Upside: +21.37%
Alnylam Pharmaceuticals
Jan 12, 2026
Maintains: Buy
Price Target: $520 → $529
Current: $349.58
Upside: +51.32%
Rhythm Pharmaceuticals
Jan 9, 2026
Maintains: Buy
Price Target: $145 → $148
Current: $102.67
Upside: +44.15%
Vaxcyte
Jan 7, 2026
Maintains: Buy
Price Target: $90 → $110
Current: $51.37
Upside: +114.13%
Gilead Sciences
Nov 13, 2025
Maintains: Buy
Price Target: $133 → $140
Current: $139.72
Upside: +0.20%
Ionis Pharmaceuticals
Oct 30, 2025
Maintains: Buy
Price Target: $78 → $90
Current: $81.92
Upside: +9.86%
Avidity Biosciences
Oct 27, 2025
Downgrades: Hold
Price Target: $65
Current: $72.46
Upside: -10.30%
Moderna
Oct 20, 2025
Reiterates: Hold
Price Target: n/a
Current: $45.30
Upside: -
Stoke Therapeutics
Oct 10, 2025
Maintains: Buy
Price Target: $22 → $35
Current: $29.40
Upside: +19.05%
Phathom Pharmaceuticals
Jun 6, 2025
Maintains: Buy
Price Target: $28
Current: $13.84
Upside: +102.31%
May 22, 2025
Reiterates: Buy
Price Target: $14
Current: $7.57
Upside: +84.94%
May 13, 2025
Maintains: Buy
Price Target: $16 → $11
Current: $6.29
Upside: +74.88%
May 6, 2025
Reiterates: Hold
Price Target: n/a
Current: $477.91
Upside: -
Mar 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $1.50
Upside: -
Mar 4, 2025
Downgrades: Hold
Price Target: $10
Current: $1.25
Upside: +700.00%
Jan 24, 2024
Upgrades: Buy
Price Target: $37
Current: $25.62
Upside: +44.42%
Aug 24, 2021
Maintains: Buy
Price Target: $32 → $18
Current: $19.03
Upside: -5.41%